Ultralow Dose PET Imaging of 18F-flurpiridaz
Part of paid clinical trials in Englewood, New Jersey.
- Sponsor
- Akiva Mintz
- Study ID
- NCT07284576
- Phase
- PHASE2
- Status
- Enrolling By Invitation
Conditions
- Coronary Arterial Disease
- Healthy Volunteer
- Myocardial Infarction
- Myocardial Ischemia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 120 Years
- Healthy Volunteers
- Accepted
Interventions
- 18F-flurpiridaz — DRUGParticipants will be injected with 18F-flurpiridaz and imaged for up to 3 hours on a PET scanner
Study Details
The goal of this clinical trial is to evaluate an investigational ultralow dose positron emission tomography (PET) imaging technique for known or suspected coronary artery disease (for detecting myocardial ischemia or infarction) detection and monitoring. The main question it aims to answer is: Can the investigators optimize the timing, scan duration, and image reconstruction to reduce the radiation dose 10-100 fold of the current clinical standard? Participants will be injected with a radioactive tracer called Fluorine-18 (18F)-flurpiridaz and be imaged on a new type of high sensitivity PET scanner for up to 3 hours
Key Dates
- Start date
- Dec 16, 2025
- Status verified
- Apr 2026
- Primary completion
- Jun 30, 2030
- Completion
- Jun 30, 2030
Study Design
- Enrollment
- 200 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DIAGNOSTIC
Arms
- Other: ultralow dose 18F-flurpiridaz imaging groupParticipants will be enrolled for an ultralow dose PET scan to evaluate image quality and optimize timing and reconstruction after reducing radiation doses 10-100 fold. Participants will be injected with a very small amount of radiotracer and imaged on a PET scanner for up to 3 hours
Primary Outcome Measure
Signal-to-Noise Ratio (SNR) [ Time Frame: Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period. ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Nuclear Imaging Institute | Englewood | New Jersey | 07631 | - |
Find similar trials in Englewood, NJ
Related Studies
- AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable MonitorRecruiting · Peerbridge Health, Inc · Orange, California
- Ultralow Dose PET Imaging for PSMA ExpressionPHASE2 · Recruiting · Akiva Mintz · Englewood, New Jersey
- Ultralow Dose PET Imaging of 18F-FDG UptakePHASE2 · Recruiting · Akiva Mintz · Englewood, New Jersey
- Ultralow Dose PET Imaging for 18F-NaF UptakePHASE2 · Recruiting · Akiva Mintz · Englewood, New Jersey